Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 16, 2026 16:05 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...
October 05, 2026 08:00 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT to Host Investor Day on October 21, 2026

Company to share insights on the advancing clinical profile and commercial vision for 4D-150Renowned retinal experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Carl C. Awh, MD, FASRS; Dr. David...
September 28, 2026 08:00 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME

4D-150 is advancing into Phase 3 development for DME, a second multi-billion-dollar retinal disease market with significant unmet need First patients have been enrolled in 4SIGHT global Phase 3 trial...
September 11, 2026 16:05 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and...
August 25, 2026 08:00 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...
August 14, 2026 16:05 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...
August 13, 2026 16:05 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

Completed enrollment for 4D-150 4FRONT-2 wet AMD Phase 3; topline data expected in H2 2027 4D-150 4FRONT-1 Phase 3 topline data expected in Q2 2027Presented positive 2-year data from 4D-150 PRISM...
July 18, 2026 15:15 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population

After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction through 2 years 4D-150 continues to be well...
July 17, 2026 16:05 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...
June 30, 2026 16:05 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists

EMERYVILLE, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...